BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
ZBTB7A
,
T cell receptor signaling pathway
,
Obesity
,
Lymphocyte
,
Alcohol
,
Cisplatin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
tecogalan
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Antiangiogenic drugs for chemotherapy of bladder tumours.
The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo.
The suppressive effect of tecogalan sodium on in vitro angiogenesis via the periendothelial proteoly…
Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and e…
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Tecogalan Sodium
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ